Brief: Biogen Enters Into Agreement With Tj Biopharma For Felzartamab Assets In The Greater China Region
20/04/2026 12:57
Biogen Inc BIIB.O: BIOGEN ENTERS INTO AGREEMENT WITH TJ BIOPHARMA FOR FELZARTAMAB ASSETS IN THE GREATER CHINA REGION BIOGEN - DEAL VALUED UP TO $850 MILLION PLUS ROYALTIES FOR TJ BIOPHARMA BIOGEN - TO LEAD DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION OF FELZARTAMAB IN GREATER CHINA REGION Source text: ID:nGNX6l8HQ6 Further company coverage: BIIB.O
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout